Want to see SE:SEZI full AI Analyst Report?
SEZI Stock Chart & Stats
kr3.64
kr0.08(2.22%)
At close: 4:00 PM EDT
kr3.64
kr0.08(2.22%)
Day’s Range― - ―
52-Week Rangekr2.35 - kr6.24
Previous CloseN/A
Volume133.90K
Average Volume (3M)818.37K
Market Cap
kr446.49M
Enterprise Valuekr665.00M
Total Cash (Recent Filing)kr37.11M
Total Debt (Recent Filing)kr21.37M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding157,215,040
10 Day Avg. Volume885,940
30 Day Avg. Volume818,373
Financial Highlights & Ratios
PEG Ratio1.41
Price to Book (P/B)2.61
Price to Sales (P/S)7.63
P/FCF Ratio-7.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.2
Revenue Forecast (FY)kr127.70M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage provides Senzime with greater financial flexibility than a heavily debt-funded medical-device business. Modest interest obligations reduce near-term solvency pressure and preserve more capacity to support commercialization while the company works toward profitability.
Long-Term Commercialization ProgressThe substantial revenue scale-up from 2021 through 2025 indicates that Senzime has made meaningful commercialization progress and established demand for its monitoring products. A larger revenue base can improve operating leverage if adoption and recurring consumable use continue to expand.
Improved Gross MarginImproving gross margin suggests that product economics have strengthened as Senzime has scaled, potentially reflecting a more favorable mix or better commercial efficiency. If maintained, this provides a stronger foundation for eventual operating leverage and improved profitability as revenue grows.
Bears Say
Persistent Cash BurnPersistent negative operating and free cash flow means Senzime is not yet funding its operations internally. Continued cash burn can require additional financing, limiting strategic flexibility and exposing the business to funding pressure if losses remain high over the next several quarters.
Deep Operating LossesThe very large net loss and negative operating margins show that the current cost base remains well ahead of revenue generation. This weak earnings foundation reduces resilience, delays self-funded growth, and makes future financial improvement dependent on substantial operating progress.
Stalled Recent Revenue MomentumSharp negative TTM revenue growth is a material concern because it can delay the company’s path to operating leverage and weaken the benefits of its installed-base model. A sustained slowdown would make it harder to absorb fixed costs and reduce ongoing funding needs.
Senzime AB News
SEZI FAQ
What was Senzime AB’s price range in the past 12 months?
Senzime AB lowest stock price was kr2.35 and its highest was kr6.24 in the past 12 months.
What is Senzime AB’s market cap?
Senzime AB’s market cap is kr446.49M.
When is Senzime AB’s upcoming earnings report date?
Senzime AB’s upcoming earnings report date is Oct 29, 2026 which is in 9 days.
How were Senzime AB’s earnings last quarter?
Senzime AB released its earnings results on Jul 16, 2026. The company reported -kr0.136 earnings per share for the quarter.
Is Senzime AB overvalued?
According to Wall Street analysts Senzime AB’s price is currently Overvalued.
Does Senzime AB pay dividends?
Senzime AB does not currently pay dividends.
What is Senzime AB’s EPS estimate?
Senzime AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Senzime AB have?
Senzime AB has 157,215,040 shares outstanding.
What happened to Senzime AB’s price movement after its last earnings report?
Senzime AB reported an EPS of -kr0.136 in its last earnings report. Following the earnings report the stock price went down -4.496%.
Which hedge fund is a major shareholder of Senzime AB?
Currently, no hedge funds are holding shares in SE:SEZI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Senzime AB
Senzime AB (publ) is a medical technology firm specializing in the creation and distribution of advanced patient monitoring solutions. These systems are designed to oversee patients undergoing anesthesia across various global markets, including Europe, Oceania, Asia, Canada, and the United States. Among its primary offerings is the TetraGraph, a sophisticated monitor designed to assess and display muscle function in surgical patients administered neuromuscular blocking agents, by stimulating, measuring, and analyzing responses. This system is complemented by the TetraSens electrode array, featuring two proximal stimulating electrodes for precise recording and reference. For data management, TetraConnect serves as a portal, allowing clinicians to conveniently access, view, and export TetraGraph data records in PDF or Excel formats. Furthermore, TetraGraph Device Connectivity facilitates the transfer of data from the TetraGraph Monitor to other patient monitoring systems, while the TetraGraph Philips Interface specifically enables the transmission of critical neuromuscular monitoring parameters—such as TOFC, TOFR, PTC, and TOF bars—to Philips patient monitors, with readings visible on the Philips Intellivue Monitor. Senzime is also actively developing the CliniSenz Analyzer, intended for continuous postoperative patient monitoring within hospital settings. Another innovation in its pipeline is the Onzurf Probe, a sterile, CE-marked single-use device leveraging micro-dialysis technology for continuous sampling from gastrointestinal organs, including the esophagus, stomach, and liver. The company maintains a strategic licensing and connectivity partnership with Masimo. This collaboration focuses on developing and commercializing the TetraGraph Smart Cable Module, designed to integrate seamlessly with Masimo's Root monitoring system and their digital hubs, thereby enabling interaction with hospital clinical information systems and electronic health records. Established in 1999, Senzime AB (publ) operates from its headquarters in Uppsala, Sweden.
Technical Analysis
Paxman AB
―
SciBase Holding AB
―
Bactiguard Holding AB
―
Acarix AB
―
Sedana Medical AB
―